Extracellular Ca 2ϩ -sensing receptor (CaSR) has been recently identified in rat and mouse pituitary and in AtT-20 cells. The aim of the study was to investigate the presence of CaSR in the human pituitary and its signaling pathway. Normal parathyroid biopsies, autoptic normal pituitaries, and seven nonfunctioning and six GHsecreting adenomas were studied. Southern blot analysis of the RT-PCR products from pituitary adenomas indicated that the PCR fragments obtained were products of specific amplification of CaSR messenger ribonucleic acid. Sequence analysis showed nucleotide identity of these products with the available human parathyroid CaSR. By immunoblotting analysis CaSR, was detected in normal and adenomatous pituitary tissues. In all tumors studied, extracellular Ca 2ϩ (2.5 mmol/L) induced a significant increase in intracellular Ca 2ϩ , mainly due to Ca 2ϩ mobilization (from 82.7 Ϯ 11 to 148 Ϯ 36 nmol/L; P Ͻ 0.001). Similar results were obtained with the CaSR activators gadolinium and neomycin. Moreover, CaSR activators significantly increased cAMP levels; this effect was not mimicked by other agents able to increase intracellular Ca 2ϩ , such as TRH. CaSR agonists did not increase resting GH secretion in any GH-secreting adenomas, but amplified the GH response to GHRH. In this study we first demonstrate CaSR expression in the human pituitary and provides evidence for an additional mechanism by which calcium might regulate pituitary cell function. (J Clin Endocrinol Metab 84: 2848 -2853, 1999) 
Ca 2ϩ (2.5 mmol/L) induced a significant increase in intracellular Ca 2ϩ , mainly due to Ca 2ϩ mobilization (from 82.7 Ϯ 11 to 148 Ϯ 36 nmol/L; P Ͻ 0.001). Similar results were obtained with the CaSR activators gadolinium and neomycin. Moreover, CaSR activators significantly increased cAMP levels; this effect was not mimicked by other agents able to increase intracellular Ca 2ϩ , such as TRH. CaSR agonists did not increase resting GH secretion in any GH-secreting adenomas, but amplified the GH response to GHRH. In this study we first demonstrate CaSR expression in the human pituitary and provides evidence for an additional mechanism by which calcium might regulate pituitary cell function. (J Clin Endocrinol Metab 84: 2848 -2853, 1999) I ONIZED calcium (Ca 2ϩ ) is the most common signal transduction element in cells, from bacteria to specialized neurons. In endocrine cells Ca 2ϩ is an important trigger of hormone secretion, as extracellular Ca 2ϩ is required for both basal and stimulated secretory activity that in the absence of the ion is markedly inhibited. Excitable cells, such as pituitary cells, contain voltage-dependent Ca 2ϩ channels that enable them to markedly increase cytosolic Ca 2ϩ levels ([Ca 2ϩ ]i) in response to depolarization from the resting membrane potential (1, 2) . Moreover, several hypothalamic neurohormones use the Ca 2ϩ molecule to transduce their signals. By interacting with specific receptors coupled to G proteins, particularly to G q , these neuropeptides, such as TRH, GnRH, and vasopressin, activate phospholipase C and induce inositol 1,4,5-trisphosphate formation and a rise in [Ca 2ϩ ]i (3) (4) (5) . Recently, a Ca 2ϩ -sensing receptor (CaSR) that mediates the inhibition of PTH secretion has been identified and cloned from bovine parathyroid gland (6) . CaSR is a G proteincoupled receptor, and its activation results in increases in inositol phosphate turnover and [Ca 2ϩ ]i (7, 8) . Transcripts that hybridize with probes of the cloned CaSR are expressed in a number of tissues of different species (7) (8) (9) . Recently, CaSR expression has been documented in mouse and rat anterior pituitary, whereas the intracellular signaling elicited by CaSR activation has been investigated in mouse corticotroph AtT-20 cells (10, 11) . We show here that a similar CaSR receptor is also expressed in human pituitary cells, and its activation modulates [Ca 2ϩ ]i and cAMP levels.
Materials and Methods Tissues
The study includes 13 human pituitary adenomas [7 nonfunctioning adenomas (NFPA) and 6 GH-secreting adenomas (GH-omas) diagnosed on the basis of clinical features and standard hormonal criteria], a pool of autoptic normal pituitaries obtained from postmortem proceedings carried out within 24 h after death, and a pool of normal parathyroid biopsies from patients operated on for primary hyperparathyroidism. The presence of G s ␣ gene mutations in GH-omas was ruled out as previously described (12) . No patient had previously undergone pituitary irradiation. Immunohistochemistry, carried out as previously described (13) , showed a high percentage of cells positive for GH in GHomas, whereas the large majority of cells from NFPA were positive for glycoprotein hormone subunits. Part of the tissue was quickly frozen at Ϫ80 C, and part was placed in sterile culture medium for cell culture. The study was approved by the local ethical committee. Informed consent was obtained from all patients.
RT-PCR
Total ribonucleic acid (RNA) was extracted from tissues according to the method of Chomczynski and Sacchi (14) . To avoid any amplification from genomic DNA contamination, the samples were pretreated with deoxyribonuclease. Total RNA was used to perform RT as previously described (15) . Briefly, 1 g total RNA was incubated for 1 h at 42 C in the presence of 2.5 U reverse transcriptase; 1 U ribonuclease inhibitor; 2.5 mol/L random hexamers; 1 mmol/L each of deoxy (d)-ATP, dCTP, dGTP, and dTTP; 5 mmol/L of MgCl 2 ; 50 mmol/L KCl; and 50 mmol/L Tris-HCl (pH 8.3) in a total volume of 20 L (GeneAmp, Perkin Elmer Corp., Norwalk, CT). Subsequently, the reaction mixture was heated at 96 C for 5 min and quick-chilled on ice. The total volume of the reactions was subjected to PCR amplification using specific primers amplifying a fragment of 330 bp. The sense primer corresponds to nucleotides 385-405 (5Ј-AGCTGCTGCTGGGTCCTCTTGG-3Ј), and the antisense primer is complementary to nucleotides 693-715 (5Ј-CAAAACTCAGGGTG-GCTTCCAAG-3Ј) of the human CaSR complementary DNA (16) . PCR amplification was performed adding to the product of RT: 50 mmol/L KCl, 50 mmol/L Tris-HCl (pH 8.3), 2 mmol/L MgCl 2 , 15 pmol of each primer, and 2.5 U Taq DNA polymerase (AmpliTaq). The reaction mix was subjected to denaturation at 94 C for 3 min, followed by 35 cycles of 94 C for 1 min, 66 C for 45 s, and 72 C for 1 min. A final cycle at 72 C for 10 min was carried out to allow complete extension of the amplified fragments. The amplified products were visualized on a 3% agarose gel stained with ethidium bromide.
Southern blot analysis
Southern blot analysis was performed using a 26-oligonucleotide probe corresponding to nucleotides 554 -579 (5Ј-TCAGGTATAATTTC-CGTGGGTTTCGC-3Ј) of human CaSR complementary DNA (16) . PCR products were fractionated on a 3% agarose gel in 1 ϫ Tris-borateethylenediamine tetraacetate and then transferred to a Hybond Ϫ Nϩ (Amersham Pharmacia Biotech Buckinghamshire, UK) Nytran membrane. The probe was ␥-32 P 5Ј-end labeled using T4 polymerase kinase for 1 h at 37 C. The blot was hybridized with the ␥-32 P-labeled internal probe for 12 h in 6 ϫ SSC (standard saline citrate), 5 ϫ Denhart's solution, 0.1% SDS, and 0.1 mg/mL salmon sperm. After hybridization, the blot was washed twice in 2 ϫ SSC and 0.1% SDS for 15 min at room temperature and subsequently in 0.1 ϫ SSC and 0.1% SDS at 65 C for 15 min. The filter was then exposed to an x-ray film (X-Omat, Eastman Kodak Co., Rochester, NY) for 12 h.
Sequencing of the RT-PCR fragment of CaR
Sequencing of the RT-PCR products using both sense and antisense specific primers was performed using the AmpliTaq BigDye Terminator kit and 310 Genetic Analyzer (Perkin Elmer Corp., Applied Biosystems, Foster City, CA).
Western blot analysis
Western analysis of CaSR protein was performed using antiserum raised in rabbits (Primm srl, Milan, Italy) against a peptide corresponding to amino acids 345-359 within the predicted extracellular domain of the deduced amino acids sequence of the bovine parathyroid CaSR (GenBank accession no. 67307) and identical to corresponding peptide in the human CaSR (17) . The protein concentration of parathyroid and pituitary tissues was measured using the Micro BCA protein reagent kit (Pierce Chemical Co., Rockford, IL). Total proteins (20 g) were separated by SDS-PAGE at 7.5% and transferred electrophoretically to nitrocellulose membranes, using mol wt standards as a reference. Proteins on membranes were detected by staining with Ponceau S. The filters were then incubated with blocking solution (20 mmol/L Tris, 500 mmol/L NaCl, and 0.2% dry milk) at 4 C overnight. The filters were subsequently incubated with antiserum against CaSR at a 1:1000 dilution for 2 h at room temperature and then with goat antirabbit IgG antibody conjugated to alkaline phosphatase for 30 min. The membranes were treated with chemiluminescent substrate and enhancer (Immuno-Star Chemiluminescent Protein Detection Systems, Bio-Rad Laboratories, Inc., Richmond, CA) and exposed to x-ray film for 5-20 min. The bands were quantitated by scanning densitometry using an imaging densitometer (Bio-Rad Laboratories, Inc., GS-670). To detect the specificity of the reaction, the antiserum was preincubated with 0.5 g/L peptide, against which the antibody was raised for 12 h at 4 C.
Cell culture
Cells were enzymatically dispersed from tumoral tissues using trypsin and deoxyribonuclease as previously described (18) . Cells were cultured at a density of 5 ϫ 10 5 cell/mL in Ham's F-10 medium (containing 0.5 mmol/L Ca 2ϩ ) supplemented with 5% FCS and antibiotics for short term incubation (24 -48 h) at 37 C and 5% CO 2 . Cells were either maintained in suspension and collected for [Ca 2ϩ ]i measurements after 16 -24 h or plated in 24-well plates for 24 -48 h and used for cAMP and GH assays.
Measurement of cytosolic Ca 2ϩ
[Ca 2ϩ ]i measurements were carried out as previously described (18) . Briefly, cells were resuspended in Krebs-Ringer HEPES incubation medium and loaded with the Ca 2ϩ indicator fura-2 by incubating the cells with 5 mol/L fura-2/acetoxymethylester (fura-2/AM) for 30 min at 37 C. Fluorescence recordings were carried out with a cell concentration of 3-4 ϫ 10 5 /mL in a Perkin Elmer Corp. LS5 spectrofluorometer (Norwalk, CT) at 345 nm excitation and 490 nm emission, with slits of 5 and 10 nm, respectively. [Ca 2ϩ ]i was calculated according to the method of Grynckievicz et al. (19) .
Intracellular cAMP assay
Cells were used for intracellular cAMP assay as previously described (12) . Medium was removed, and cell monolayers were washed and equilibrated for 1 h with a solution containing 125 mmol/L NaCl, 5 mmol/L KCl, 0.5 mmol/L MgSO 4 , 0.5 mmol/L CaCl 2 , 25 mmol/L HEPES (pH 7.4), 6 mmol/L glucose, and 0.1% BSA. Cells were treated for 10 min with 2 mmol/L isobutylmethylxanthine followed by a 30-min incubation with the agents to be tested. After medium removal, cells were washed, and cAMP was extracted with 1 mL ice-cold ethanol (80%) at Ϫ20 C for 24 h. The supernatants were evaporated to dryness and redissolved in cAMP kit buffer (Amersham Pharmacia Biotech, Buckinghamshire, UK) as previously described (12) .
In vitro hormone release
Medium was removed by aspiration, and the cell monolayers were washed twice and preincubated for 1 h with fresh Ham's F-10 medium supplemented with 0.1% BSA. Cells were then incubated with and without the agents to be tested for 30 min at 37 C in triplicate. At the end of incubation, the medium was removed and stored at Ϫ20 C until GH assay (Wallac Oy, Tuzku, Finland). 
Statistical analysis
The results are expressed as the mean Ϯ sd. Paired or unpaired two-tailed Student's t test was used to detect the significance between two series of data. P Ͻ 0.05 was accepted as statistically significant.
Results

Identification of CaSR messenger RNA (mRNA)
Total RNA extracted from human parathyroid, two NFPA, and two GH-secreting adenomas was subjected to RT-PCR using specific primers amplifying a 330-bp fragment of the CaSR. The products of RT-PCR showed a single fragment of the expected size in all tissues (Fig. 1) . The band was absent when RT was omitted from reverse transcriptase reaction Ca 2ϩ -SENSING RECEPTOR IN HUMAN PITUITARY (Fig. 1) . The Southern blot analysis, performed in all RT-PCR products, revealed that in each of the samples the internal probe hybridized to the 330-bp fragment, confirming that they were products of specific amplification of CaSR mRNA expressed in these tissues (Fig. 1) . Sequence analysis of the 330-bp fragments generated by RT-PCR from pituitary (one NFPA) and parathyroid tissues indicated a 100% homology of this portion of CaSR with the previously reported sequence of the human parathyroid gland (16) . Figure 2 shows immunoblots obtained with the antiserum directed against CaSR in normal parathyroid tissues and in normal and tumoral pituitary, which were run simultaneously in each experiment. Probing with this antiserum detected one single band of approximately 150 kDa, that was absent after preabsorbing the antiserum with the peptide against which it was raised. The protein was expressed at high levels in the normal pituitary and in the adenomas tested (three NFPA and three GH-omas); the amount of CaSR was similar to that found in the parathyroid (Fig. 2) . ]o and other CaSR activators, such as Gd 3ϩ and neomycin, resulted in a typical biphasic [Ca 2ϩ ]i rise composed of a rapid increase, followed by a plateau that was maintained for several minutes (Fig. 4) . The initial peak was maintained in nominally Ca 2ϩ -free medium, indicating that this component was due to Ca 2ϩ release from intracellular stores (Fig. 4) . The blockade of L-type Ca 2ϩ channels by nimodipine caused a rapid decrease in resting [Ca 2ϩ ]i levels, with a reduction from 35-54% (Fig. 4) . Moreover, this agent reduced the transient due to Ca 2ϩ mobilization and abolished the plateau phase due to Ca 2ϩ influx caused by CaSR activation. The effects of CaSR activators on [Ca 2ϩ ]i were not modified by PTX pretreatment (0.1 g/mL for 16 h).
Expression of CaSR protein
Effect of CaSR agonists on [Ca
TRH (100 nmol/L) caused a 2-to 2.5-fold increase in [Ca 2ϩ ]i in all NFPA and GH-omas (Fig. 4) . The increases induced by TRH were higher than those triggered by [Ca 2ϩ ]o (stimulation, 162 Ϯ 50% by TRH vs. 74 Ϯ 40% by [Ca 2ϩ ]o; P Ͻ 0.05). [Ca 2ϩ ]o at 1.5 mmol/L caused a significant stimulation of intracellular cAMP levels in six tumors (four NFPA and two GH-omas), whereas further [Ca 2ϩ ]o increases to 2.5 mmol/L were effective in the remaining four (Fig. 5) . Similarly, Gd , and N7), and three GH-secreting adenomas (G1, G2, and G6). Controls for immunoblotting were tissues from a parathyroid pool (c), one nonfunctioning pituitary adenomas (c7), and one GH-oma (c6) subjected to antiserum preincubated with 0.5 g/L peptide at 4 C for 12 h (C).
Effects of CaSR agonists on intracellular cAMP levels
tested (two NFPA and one GH-oma; Fig. 5 ). Pretreatment of cells from two NFPA with PTX did not affect cAMP increase induced by [Ca 2ϩ ]o. Intracellular cAMP levels were significantly increased by specific hypothalamic peptides. In particular, 10 nmol/L GHRH was more effective than [Ca 2ϩ ]o in increasing cAMP levels in GH-omas (stimulation, 410 Ϯ 282% by GHRH vs. 97.8 Ϯ 80.4% by [Ca 2ϩ ]o; P Ͻ 0.05), whereas PACAP and [Ca 2ϩ ]o elicited similar cAMP responses in NFPA (stimulation, 110 Ϯ 82% by PACAP vs. 97.8 Ϯ 80.4% by [Ca 2ϩ ]o; P ϭ NS). In the tumors tested (two NFPA and two GH-omas), TRH at any concentration (from 10 nmol/L to 10 mol/L) was unable to modify cAMP levels (1.27 Ϯ 0.64 pmol/well cAMP in the absence vs. 1.30 Ϯ 0.50 pmol/well cAMP in the presence of 10 mol/L TRH; P ϭ NS).
In vitro hormone release
Hormone secretion in the presence of different [Ca 2ϩ ]o concentrations was evaluated in GH-omas. [Ca 2ϩ ]o, at concentrations of 1.5 and 2.5 mmol/L, did not significantly increase in vitro GH release in resting conditions (basal GH, 30.8 Ϯ 2.1 ng/well⅐30 min vs. 32.1 Ϯ 2.9 at 2.5 mmol/L [Ca 2ϩ ]o; P ϭ NS), but caused an amplification of GHRHinduced stimulation (Fig. 6) . Similarly, Gd 3ϩ , which was ineffective on basal GH release, increased the GH response to GHRH (Fig. 6 ).
Discussion
Previous studies have shown that changes in [Ca 2ϩ ]o modulate hormonal secretion from anterior pituitary (20 -22) . The stimulatory action of [Ca 2ϩ ]o on secretory processes was mainly attributed to the presence of calcium channels in these cells (1) (2) (3) (4) (5) . More recently, it has been demonstrated that the rat and mouse pituitary and AtT-20 cells express a CaSR similar to that originally cloned in the bovine parathyroid (10, 11) . In the present study we first demonstrate that a CaSR is expressed in human pituitary cells. In fact, RT-PCR analysis of total RNA in the presence of primers expected to amplify a region coding part of the extracellular domain of the receptor showed a single band of 330 bp in all pituitary tissues tested. Southern blot analysis of the RT-PCR products, performed using a probe corresponding to nucleotides 554 -579 of human CaSR, confirmed that the PCR fragments were products of specific amplification of CaSR mRNA expressed in each of the four pituitary samples. Moreover, sequence analysis of the PCR fragments revealed that this portion of the receptor is identical to the previously published sequence of the human parathyroid CaSR (16) .
Immunoblotting performed with an antiserum directed against the extracellular domain of the receptor showed that in pituitary cells, CaSR mRNA is translated into a functional protein. Although previous works reported that this antiserum recognized a doublet of about 130 and 150 kDa, representing a different degree of glycosylation of the receptor (6, 17) , in our experimental conditions a single band of approximately 150 kDa was detected; the gel system we used did not allow the accurate identification of the two forms. CaSR was clearly detected in normal pituitary and pituitaries of different types, without quantitative differences from the amounts found in parathyroid tissues. These data suggest that expression of CaSR is a common feature of the pituitary cell that seems to be independent from its normal or tumoral origin as well as its secretory activity.
In cells obtained from each of the tumors, CaSR agonists caused a significant increase in [Ca 2ϩ ]i that was mainly due to Ca 2ϩ mobilization, in agreement with the stimulation of phospholipase C and inositol phosphate production induced by CaSR activation in other cell systems (7, 8, 10, 11) . Increases in [Ca 2ϩ ]i observed in pituitary cells were similar to those observed in AtT20, but definitely lower than those reported in the parathyroid (10) . As the levels of CaSR expression in pituitary and parathyroid tissues were similar, different efficiencies of CaSR coupling to endogenous G proteins might account for the differences between the two systems. Contrary to the results obtained in AtT-20 cells (10), in human pituitary cells CaSR seems to be coupled to a PTXinsensitive G protein, probably G q and/or G 11 . This coupling is similar to that reported in the human parathyroid (23), suggesting the existence of species-and cell-specific differences in the pattern of G proteins available for CaSR activation. Calcium mobilization occurred between 1.5-2.5 mmol/L [Ca 2ϩ ]o, which is consistent with the maximal stimulation of inositol phosphate production occurring at 3 mmol/L [Ca 2ϩ ]o in AtT20 cells (10) . Although in the parathyroid, CaSR activation induces [Ca 2ϩ ]i increases associated with the reduction of both intracellular cAMP levels and PTH release (8, 24) , in AtT20 cells the activation of the same receptor causes a significant increase in cAMP levels, which is consistent with the marked increase in both basal and CRH-stimulated ACTH secretion induced by [Ca 2ϩ ]o elevation (10, 11) . The same receptortriggered events were observed in human pituitary cells, in which a significant stimulation of cAMP levels was caused by [Ca 2ϩ ]o and CaSR agonists. The molecular mechanisms involved in cAMP generation by [Ca 2ϩ ]o are unknown at the present time. However, the observation that stimulation of both Ca 2ϩ mobilization and influx induced by other agents, i.e. TRH, did not affect cAMP levels points to a direct, receptor-specific action of [Ca 2ϩ ]o on cAMP production. The relationship between hormone secretion and activation of CaSR is unclear. Indeed, in vivo and in vitro studies suggest a modulatory role of [Ca 2ϩ ]o in the secretion of pituitary hormones (20, 21, (25) (26) (27) (28) (29) (30) , although few and contradictory data have been obtained at Ca 2ϩ concentrations within the normal physiological range (31, 32) . Activation of CaSR did not result in hormone secretion from any of GHomas studied, although it is worth noting that hypothalamic peptides known to stimulate in vitro GH release from cultured tumors, such as GHRH and TRH, increased cAMP production and cytosolic Ca 2ϩ levels, respectively, at a greater extent than [Ca 2ϩ ]o. However, although CaSR seems to be devoid of a direct effect on hormone secretion, one might postulate that small changes in intracellular calcium and cAMP levels by [Ca 2ϩ ]o may influence the action of classical hypothalamic releasing hormones. This view is supported by our observation that the GH response to GHRH in GH-omas was amplified by activating CaSR.
In conclusion, we first demonstrate the expression of the CaSR mRNA and the protein it encodes in the human pituitary. In addition, we demonstrate that the activation of this receptor generates a series of intracellular effectors that are known to control several biological processes, including hormone secretion and cell differentiation and proliferation, thus providing evidence for an additional mechanism by which calcium might regulate pituitary cell function.
